Get 50% OFF This Summer!
Global Health
No Data Available
No Stocks
Unlock Smart Score
See Detailed Analysis & Insights
Unlock Insights
See Detailed Analysis & Insights
No Research Report
ROE
Avg ROE (3 Yrs) : NaN%
ROCE
Avg ROCE (3 Yrs) : NaN%
ROA
Avg ROA (3 Yrs) : NaN%
NPM
Avg NPM (3 Yrs) : NaN%
No Data Available
Unlock Management Data
See Detailed Analysis & Insights
Global Health Limited was incorporated as Global Health Private Limited' on August 13, 2004 at New Delhi, India as a Private Limited Company under the Companies Act, 1956. The Company converted into a Public Limited Company, passed by Shareholders at the EGM held on July 31, 2021 and consequently, name of the Company was changed to Global Health Limited' dated August 11, 2021 issued by the RoC.
The Company was founded by Dr. Naresh Trehan, a world-renowned cardiovascular and cardiothoracic surgeon. The Company is one of the largest private multi-speciality tertiary care providers operating in the North and East regions of India in terms of bed capacity with key specialties of cardiology and cardiac science, neurosciences, oncology, digestive and hepatobiliary sciences, orthopaedics, liver transplant, and kidney and urologoly. Under the 'Medanta' brand, it has a network of 5 hospitals currently in operation including, Gurugram, Indore, Ranchi, Lucknow and Patna and one hospital in Noida, which is under construction. As at June 30, 2022, the Company provide healthcare services in over 30 medical specialties and is engaged over 1,300 doctors led by experienced department heads and, spanning an area of 4.7 million sq. ft., their operational hospitals have 2,467 installed beds to serve Indian and international patients.
In November 2009, the Company opened its flagship hospital in Gurugram.
In 2015, its subsidiary, Global Health Patliputra Private Limite (GHPPL), entered into a Concession Agreement with Governor of Bihar for the development, operation and maintenance of a proposed hospital on public-private partnership at Patna.
In 2019, it commenced operations of new hospital at Lucknow.
In 2020, Patna hospital's outpatient department facility was launched and the inpatient department facility of its Patna hospital was inaugurated in October 2021, which commenced operations during year 2022.
The Company has taken in-house facility and operate pharmacies at its Gurugram, Lucknow, Indore and Ranchi hospitals as well as launched an outpatient department pharmacy at South Delhi clinic in year 2021 and launched outpatient department pharmacy at South Delhi clinic at Patna hospital in year 2022. As at June 30, 2022, it had 200 installed beds and employed over 50 doctors across key specialties such as neuroscience and cardiac sciences. Patna hospital had 228 installed beds and employed over 125 doctors as at June 30, 2022 and is designed to accommodate over 500 beds.
In the Board Meeting dated 25 January 2021, the Board of Directors of the Holding Company have approved capital raising comprising of fresh issue and offer for sale of equity shares by the existing shareholders through an Initial Public Offering (IPO)
The Company came out with a public issue during November, 2022 by raising Rs. 2205.57 crores through fresh issue amounting to Rs. 500 crores and offer for sale amounting to Rs. 1705.57 crores.
The Company's Lucknow hospital added 191 beds in FY23, including over 90 critical care beds. Lucknow hospital also added seven new OTs and have hired over 50 senior clinicians. Towards the end of FY23, Lucknow hospital commissioned the Siemens Varian EDGE Radiation Oncology machine - the first in North India - as well as set up a dedicated e-ICU Command Centre to assist in remote critical care management. The Company's Patna hospital added over 100 beds and 35+ doctors in FY23. In FY23, the Company also announced a new 300- bed hospital project in Indore under the asset-light O&M model. It started Medanta Labs in January 2023. During the year 2022-23, GHL Pharma was incorporated as a wholly-owned subsidiary on June 29, 2022.
Global Health share price reflects investor sentiment toward the company and is impacted by various factors such as financial performance, market trends, and economic conditions. Share price is an indicator which shows the current value of the company's shares at which buyers or sellers can transact.
Market capitalization of Global Health indicates the total value of its outstanding shares. Marketcap is calculated by multiplying share price and outstanding shares of the company. It is a helpful metric for assessing the company's size and market Valuation. It also helps investors understand how Global Health is valued compared to its competitors.
Global Health PE ratio helps investors understand what is the market value of each stock compared to Global Health 's earnings. A PE ratio higher than the average industry PE could indicate an overvaluation of the stock, whereas a lower PE compared to the average industry PE could indicate an undervaluation.
The PEG ratio of Global Health evaluates its PE ratio in relation to its growth rate. A PEG ratio of 1 indicates a fair value, a PEG ratio of less than 1 indicates undervaluation, and a PEG ratio of more than 1 indicates overvaluation.
Return on Equity (ROE) measures how effectively Global Health generates profit from shareholders' equity. A higher ROE of more than 20% indicates better financial performance in terms of profitability.
Return on Capital Employed (ROCE) evaluates the profitability of Global Health in relation to its capital employed. In simple terms, ROCE provides insight to investors as to how well the company is utilizing the capital deployed. A high ROCE of more than 20% shows that the business is making profitable use of its capital.
Total debt of Global Health shows how much the company owes to either banks or individual creditors. In simple terms, this is the amount the company has to repay. Total debt can be a very useful metric to show the financial health of the company. Total debt more than equity is considered to be a bad sign.
The Debt-to-Equity (DE) ratio of Global Health compares its total debt to shareholders' equity. A higher Debt to Equity ratio could indicate higher financial risk, while a lower ratio suggests that the company is managing its debt efficiently.
CAGR shows the consistent growth rate of Global Health over a specific period, whether it is over a month, a year, or 10 years. It is a key metric to evaluate the company’s long-term growth potential. Main metrics for which CAGR is calculated are net sales, net profit, operating profit, and stock returns.
Technical analysis of Global Health helps investors get an insight into when they can enter or exit the stock. Key components of Global Health Technical Analysis include:
There are usually multiple support levels, but the main support levels for a stock are S1, S2, S3. Support levels indicate price points where stock might get support from buyers, helping the stock stop falling and rise.
There are usually multiple resistance levels, but the main resistance levels for a stock are R1, R2, R3. Resistance levels represent price points where Global Health shares often struggle to rise above due to selling pressure.
Dividends refer to the portion of the company’s profits distributed to its shareholders. Dividends are typically paid out in cash and reflect Global Health ’s financial health and profitability.
Bonus shares are usually given by companies to make the stock more affordable, increase liquidity, boost investor confidence, and more.
Stock split increases the number of its outstanding shares by dividing each existing share into multiple shares. When the company offers a stock split, the face value of the stock reduces in the same proportion as the split ratio.
The financials of Global Health provide a complete view to investors about its net sales, net profit, operating profits, expenses, and overall financial health. Investors can analyze financial data to assess the company’s stability and also understand how the company has been growing financially.
The profit and loss statement of Global Health highlights its net sales, net profit, total expenditure, and operating profits in the current financial year. This Profit and Loss statement is crucial for evaluating the profitability and financial stability of Global Health .
The balance sheet presents a snapshot of Global Health ’s assets, liabilities, and equity of shareholders, providing insights into the financials of the company.
Cashflow statements track the company's cash inflows and outflows over a period. It is an essential tool for understanding how well the company manages its liquidity and finances.
Download the App